Scarica l'app Stockscreener
116.23
1.93%
2.205
Dopo l'orario di chiusura:
118.90
2.67
+2.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. - Stock Titan
Non-controlling/minority interest of Corcept Therapeutics Incorporated. – HAN:HTD - TradingView
Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each - Stock Titan
Corcept Therapeutics’ oncology president sells $29,842 in stock - Investing.com
Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Canada
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT) - Yahoo Finance
Corcept Therapeutics Announces New Endocrinology Division President - The Globe and Mail
The Escalator: Bavarian Nordic, Acumetis, Corcept and more - Medical Marketing and Media
Corcept Therapeutics (CORT) Short Interest & Short Float | Updated Sep 2026 $CORT - MarketBeat
About Corcept Therapeutics Incorporated rStock - Coinbase
CORT Looks 59.9% Overvalued on GF Value™ - gurufocus.com
Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires - citybiz
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant - TradingView
Corcept names Justin Gunn to lead endocrinology division By Investing.com - Investing.com Canada
Corcept Therapeutics: Justin Gunn to Succeed Maduck, Assume New Responsibilities Starting Oct 1 >CORT - Moomoo
Corcept Announces Planned Leadership Transition - Business Wire
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus - Yahoo Finance
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle - Yahoo Finance
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Your Wyoming Link
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to S&P 400 Health Care - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM: CORT) dropped from S&P 600 - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM: CORT) dropped from S&P 600 Health Care - marketscreener.com
Corcept Therapeutics shares surge 22% after Q2 beat, guidance raise - scanx.trade
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE) - The Globe and Mail
Corcept Therapeutics president Vieira sells $29,842 of stock By Investing.com - Investing.com South Africa
Corcept Therapeutics president Vieira sells $29,842 of stock - Investing.com
Corcept Therapeutics (CORT) oncology president sells shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History - Benzinga
Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years - webull.com
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week - Seeking Alpha
Corcept Therapeutics Incorporated Receives CHMP Recommendation For EU Marketing Authorization For Lifyorli (Relacorilant) Combined With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer - marketscreener.com
CORT Looks 57.2% Overvalued on GF Value™ Amid EMA Relacorilant N - gurufocus.com
Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval - marketscreener.com
Corcept’s relacorilant receives EU panel backing for ovarian cancer By Investing.com - Investing.com Canada
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant) - STT Info
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup - ChartMill
Corcept (CORT) director offloads 10,000 shares under preset plan - Stock Titan
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? - Eastern Progress
Corcept Grows to Mid-Cap on Institutional Support - FXEmpire
Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks - Moomoo
Corcept Therapeutics (CORT) director plans $3.34M stock sale - Stock Titan
Stock option exercise to drive 10,000-share sale at Corcept (NASDAQ: CORT) - Stock Titan
Corcept Therapeutics posts strong Q2 revenue, e... - Pluang
Corcept president Sean Maduck sells $2.86m in stock By Investing.com - Investing.com South Africa
Corcept Therapeutics Insider Sold Shares Worth $2,860,737, According to a Recent SEC Filing - marketscreener.com
Corcept Therapeutics Insider Sold Shares Worth $6,460,766, According to a Recent SEC Filing - marketscreener.com
Corcept president Sean Maduck sells $2.86m in stock - Investing.com
Corcept Therapeutics oncology president sells $6.46m in shares By Investing.com - Investing.com Australia
Corcept Therapeutics oncology president sells $6.46m in shares - investing.com
Corcept Therapeutics (CORT) CFO adds shares via plan and restricted awards - Stock Titan
Corcept (CORT) oncology president reports shares and 480K options - stocktitan.net
CORCEPT Therapeutics Officer Vieira Roberto Wandenkolk to Sell 75,295 Shares Including 74,999 Stock Options (NASDAQ: CORT) - Kalkine Media
$8.3M stock sale planned at Corcept (NASDAQ: CORT) - Stock Titan
QQQ Stock Price TodayGet QQQ News, Analysis and Trading Ideas - Stocktwits
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report? - Yahoo Finance
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - Kalkine Media
Corcept (NASDAQ: CORT) director to sell 26,685 shares - Stock Titan
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):